Evaluation of the protective effect of chamomile oral solution on the incidence of neurotoxicity caused by chemotherapy regimens containing paclitaxel in cancer patients

Mashhad University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新: 2023年10月16日

适应症

试验速览

暂无简介。

•Suffering from cancer and starting chemotherapy regimen containing paclitaxel at a dose of 175 mg/m2.
•age between 18-70 yers

•Liver failure (due to the change in drug clearance): If the ALT and AST tests are more than two to three times the normal level at the beginning of the treatment, the patient will be excluded from the study.
•Renal failure (GFR<30 ml/min)
•Neuropathy at baseline
•Having diabetes or other disorders that cause neuropathy
•Taking supplements containing antioxidant compounds
•Use of neuromodulator drugs such as compounds containing calcium or magnesium and anticonvulsant drugs such as gabapentin and antidepressants from tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors.
•Taking warfarin
•alcohol consumption
•Lack of patient satisfaction
•Having a history of allergy to chamomile
•Use of other neurotoxic drugs in the chemotherapy regimen, such as platinums or vincristine
•Suffering from concurrent neuromuscular diseases such as myasthenia gravis
•Guillain Barre syndrome, multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy

发起方